Navigation Links
Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
Date:11/5/2008

or Relations section of the company's Web site at http://investor.genomichealth.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our beliefs regarding the ability of personalized medicine to improve the quality of healthcare while reducing costs; the components of future growth, if any, in our business; our belief that including quantitative HER2 scores increases the value of Oncotype DX; our beliefs regarding continued investment in our commercial organization domestically and abroad; our beliefs regarding the strengths of our business model; the outcome or success of planned or ongoing clinical trials and our expectations regarding potential clinical outcomes; and the applicability of clinical study results to actual outcomes.
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Belmont, Mass. (PRWEB) August 27, 2014 ... of top technology vendors,” said Ven Thangaraj, CEO of ... imaging solutions that are taking the imaging corelab market ... trial sponsors, corelabs and research organizations to efficiently and ... and prepare the data to be analyzed and read ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... The Graphene Opportunity - A Rational View ... Graphene The New Nanotech? A similar amount ... of applications ranging from microelectronics to water treatment, ... announced the availability of the Graphene Opportunity Report, ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... to Initiate Phase II Trial for IPLEX(TM) in ... Sweden, Sept. 23 ,Insmed Inc. (Nasdaq CM: INSM), ... Premacure AB, a biopharmaceutical company,dedicated to the development ... to premature birth, today noted the presentation of,clinical ...
... REDWOOD CITY, Calif., Sept. 23 Codexis, Inc., ... Vice President,Intellectual Property. She will be responsible for ... portfolio and will,report to Douglas Sheehy, Vice President, ... Codexis from Danisco A/S, where as Senior,Director, Intellectual ...
... 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) today ... with Toray,Industries Inc. of Japan to obtain the ... Toraymyxin(TM), a therapeutic for the treatment of,sepsis that ... of the,agreement, the Company will seek FDA approval ...
Cached Biology Technology:Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 2Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 3Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 4Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants 5Codexis Names Vice President, Intellectual Property 2Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... in their fight against a dangerous bacterium that sickens ... such as catheters, artificial joints and heart valves. , ... has, for the first time, been shown to protect ... would otherwise kill the bacteria, according to scientists at ...
... access publishing and the NIH new policy from ... of Health (NIH) rule on Enhanced Public Access to ... and a missed opportunity to take advantage of available ... the nation's leading not-for-profit medical and scientific publishers. The ...
... follow up of the NIH public access policy announced ... Central : , BioMed Central welcomes the announcement ... access policy. The NIH calls on all of its grantees ... National Library of Medicine's PubMed Central and make them freely ...
Cached Biology News:Substance protects resilient staph bacteria 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3BioMed Central welcomes the new National Institutes of Health public access policy 2
... The ScriptCap™ 2'-O-Methyltransferase converts Cap 0 ... mRNA. The Cap 1 structure has been ... by up to 50%. This improvement is ... the ScriptCap™ m7G Capping System as well ...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: